These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22204524)

  • 1. Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies.
    Duffull SB; Graham G; Mengersen K; Eccleston J
    J Biopharm Stat; 2012; 22(1):16-29. PubMed ID: 22204524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of robust design of nonlinear models with an application to pharmacokinetics.
    Foo LK; Duffull S
    J Biopharm Stat; 2010 Jul; 20(4):886-902. PubMed ID: 20496212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.
    Dokoumetzidis A; Aarons L
    J Biopharm Stat; 2007; 17(5):851-67. PubMed ID: 17885870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models.
    Hack CE
    Toxicology; 2006 Apr; 221(2-3):241-8. PubMed ID: 16466842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
    Bos AM; Boom K; Vinks AA; Boezen HM; Wanders J; Dombernovsky P; Aamdal S; de Vries EG; Uges DR
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):64-70. PubMed ID: 15069581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.
    Daimon T; Goto M
    Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers.
    Ariano RE; Duke PC; Sitar DS
    Clin Ther; 2012 Mar; 34(3):668-76. PubMed ID: 22381713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of population pharmacokinetic experiments using prior information.
    Ogungbenro K; Aarons L
    Xenobiotica; 2007; 37(10-11):1311-30. PubMed ID: 17968747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gradient Markov chain Monte Carlo algorithm for computing multivariate maximum likelihood estimates and posterior distributions: mixture dose-response assessment.
    Li R; Englehardt JD; Li X
    Risk Anal; 2012 Feb; 32(2):345-59. PubMed ID: 21906114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
    Schoemaker NE; Mathôt RA; Schöffski P; Rosing H; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):514-7. PubMed ID: 12451480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.
    Lambert PC; Sutton AJ; Burton PR; Abrams KR; Jones DR
    Stat Med; 2005 Aug; 24(15):2401-28. PubMed ID: 16015676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models.
    Graham G; Gueorguieva I; Dickens K
    Comput Methods Programs Biomed; 2005 Jun; 78(3):237-49. PubMed ID: 15899308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies.
    Vajjah P; Duffull SB
    Pharm Stat; 2012; 11(6):503-10. PubMed ID: 23059829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two design optimality criteria applied to a nonlinear model.
    Bogacka B; Wright F
    J Biopharm Stat; 2004 Nov; 14(4):909-30. PubMed ID: 15587972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.